Pfizer Begins Submitting Applications for Biosimilars, Could Be First Major New Drug Maker to Enter Japanese Market

Pfizer Japan has begun submitting applications for domestic marketing authorization for a number of biosimilars. The first was for a biosimilar of the anti-rheumatoid arthritis (RA) drug Remicade (infliximab). Four other biosimilars are in PIII clinical development and could be...read more